Sotatercept has previously been evaluated in healthy volunteers and patients with conditions characterized by dysfunctional TGF-β superfamily signaling, including anemia associated with myelodysplastic syndromes, anemia associated with β-thalassemia, chemotherapy-induced anemia, end-stage kidney disease, bone loss, and multiple myeloma (168–174). Here, TGFB1 is linked to anemia.